Navigation Links
Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
Date:3/17/2009

HAMILTON, Bermuda, March 17 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) announced today that one of its subsidiaries and Mayne Pharma International Pty. Ltd. ("Mayne") have received a Paragraph IV Certification Notice from Impax Laboratories, Inc. ("Impax") advising that Impax has filed an Abbreviated New Drug Application (ANDA) for a generic version of DORYX 150 mg delayed-release tablets.

DORYX, which Warner Chilcott markets and sells in 150, 100 and 75 mg strengths in the United States under a license agreement with Mayne, is a tetracycline-class oral antibiotic protected by Mayne's Patent No. 6,958,161 (the "161 Patent") which expires in 2022.

The Company and Mayne are currently reviewing the detail of the Paragraph IV Certification Notice from Impax and intend to vigorously defend the 161 patent and pursue their legal rights.

About Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

Read more on http://www.warnerchilcott.com.

Warner Chilcott's Forward Looking Statements:

This press release contains forward-looking statements, including statements concerning our operations, our anticipated economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2008; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Support Legislation to Protect Kids from Tobacco
2. Virginia Faith Leaders Call on Sens. Webb & Warner to Support Legislation to Protect Kids From Tobacco
3. Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
4. Warner Chilcott Announces 2009 Financial Guidance
5. Warner Chilcott Announces 2009 Financial Guidance Conference Call
6. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
7. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
8. Warner Chilcott to Present at the 27th Annual JP Morgan Healthcare Conference
9. Warner Chilcott and Dong-A Sign U.S. License Agreement For Erectile Dysfunction Treatment
10. Warner Chilcott to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
11. Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Canadian author Mark Black is a speaker, author, ... the Heart" around the world … with the help of his publisher Strategic Book Group ... Black lay in a hospital bed waiting for a miracle: He needed a heart and ...
(Date:5/6/2016)... ... ... Multiple award winning plumbing company in San Diego, Bill Howe ... values of exceptional customer service, quality work at reasonable rates, and giving back to ... Diego plumbing, and other services including heating & air conditioning and restoration & flood ...
(Date:5/6/2016)... ... 2016 , ... In honor of Military Spouse Appreciation Day ... the National Military Family Association, a nonprofit that works to strengthen and protect ... recipient of 2016. , “Being awarded this scholarship by Career Step, is ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... ... ... While the practice and profession of Aging Life Care is not new, there ... and resources. Aging Life Care plays an important role as these professionals are prepared ... Care is a holistic, client-centered approach to caring for older adults or others facing ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... Research and Markets has announced the addition of the  ...  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Positron Emission Tomography (PET) scanner and cyclotron install base in ... France , Germany , ... the United Kingdom . Along with the ...
(Date:5/5/2016)... May 5, 2016 ... the  "Europe Thalassaemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights - 2016, ... Thalassaemia epidemiology, Thalassaemia market valuations and forecast, ...
Breaking Medicine Technology: